Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
| dc.creator | Yang, Jing | |
| dc.creator | Zheng, Ya | |
| dc.creator | Gou, Xi | |
| dc.creator | Wang, Haojia | |
| dc.creator | Wang, Yuping | |
| dc.creator | Zhou, Yongning | |
| dc.date.accessioned | 2020-07-28T20:55:33Z | |
| dc.date.available | 2020-07-28T20:55:33Z | |
| dc.date.created | 2020-03-05 | |
| dc.description.abstractenglish | Background An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. Aims The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. Methods A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. Results Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86–97%), followed by cough (67.7%, 95% CI: 59–76%), fatigue (51.0%, 95% CI: 34–68%) and dyspnea (30.4%, 95% CI: 21–40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0–27.2%) and diabetes (9.7%, 95% CI: 7.2–12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8–13.8%) and respiratory system disease (1.5%, 95% CI: 0.9–2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46–3.83), 2.46 (95% CI: 1.76–3.44) and 3.42 (95% CI: 1.88–6.22) respectively. Conclusion We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients. | spa |
| dc.format.extent | 5 páginas | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.identifier.doi | https://doi.org/10.1016/j.ijid.2020.03.017 | spa |
| dc.identifier.issn | 1201-9712 | spa |
| dc.identifier.other | https://www.ijidonline.com/article/S1201-9712(20)30136-3/fulltext#%20 | spa |
| dc.identifier.uri | https://hdl.handle.net/20.500.12010/11316 | |
| dc.publisher | International Journal of Infectious Diseases | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
| dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
| dc.subject | Comorbidities | spa |
| dc.subject | Clinical characteristics | spa |
| dc.subject | Epidemiology | spa |
| dc.subject | Meta-analysis | spa |
| dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
| dc.subject.lemb | COVID-19 | spa |
| dc.subject.lemb | SARS-CoV-2 | spa |
| dc.subject.lemb | Coronavirus | spa |
| dc.title | Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.type.local | Artículo | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- Prevalence-of-comorbidities-and-its-effects-in-patie_2020_International-Jour.pdf
- Tamaño:
- 987.25 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Documento Reservado
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 2.87 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: